<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590171</url>
  </required_header>
  <id_info>
    <org_study_id>IntReALL HR 2010</org_study_id>
    <nct_id>NCT03590171</nct_id>
  </id_info>
  <brief_title>International Study for Treatment of High Risk Childhood Relapsed ALL 2010</brief_title>
  <official_title>International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, Münster (BFM) Study Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australian and New Zealand Children's Haematology/Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Anna Kinderkrebsforschung, CCRI (co-sponsor, Austria)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Motol (Co-Sponsor Czech Republic)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Rigshospitalet (co-sponsor, Denmark)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turku University Central Hospital (co-sponsor, Finland)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Our Lady's Chilrden's Hospital (Co-Sponsor Ireland)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Pediatrico Bambino (co-sponsor, Italy)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prinses Máxima Centrum (Co-Sponsor Netherlands)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital (co-sponsor, Norway)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Wroclaw (Co-Sponsor Poland)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Português de Oncologia de Lisboa (co-sponsor, Portugal)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital Stockholm (co-sponsor, Sweden)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Children's Hospital Zürich (co-sponsor, Switzerland)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Manchester University Hospitals NHS Foundation Trust (co-sponsor, UK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to improve the outcome of children and adolescents with acute
      lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies
      within a large international trial and the integration of new agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Though survival of children with acute lymphoblastic leukemia (ALL) has considerably improved
      over the past few decades, relapsed ALL remains a leading cause of mortality in children with
      cancer. Risk has been defined by the International (I) Berlin, Frankfurt, Münster (BFM) Study
      Group (SG) based on duration of first remission, immunophenotype of malignant clone, and site
      of relapse. Patients classified as high risk (HR) by these criteria have poor response rates
      to standard induction therapy, high rates of subsequent relapse and require an allogeneic
      hematopoetic stem cell transplantation (allo-HSCT) for consolidation of 2nd remission. Over
      the last decade members of the I-BFM-SG have investigated the use of different combinations
      of conventional cytotoxic agents. Even with allo-HSCT, none of these approaches have improved
      outcome above 40%. Therefore, for HR patients there is a need to investigate the curative
      potential of new agents combined with systemic therapy. The proteasome inhibitor bortezomib
      has shown synergistic activity with acceptable toxicity when combined with corticosteroids,
      anthracyclines and alkylating agents in adult patients with cancer as well as with
      dexamethasone, doxorubicin, vincristine and polyethylene glycol (PEG) asparaginase in
      children with refractory or relapsed ALL. In the I-BFM-SG International Study for Treatment
      of High Risk Childhood Relapsed ALL (IntReALL) HR 2010 study, the potential of Bortezomib
      combined with a modified ALL relapse protocol 3 (R3) backbone as induction regimen for HR
      patients to improve complete 2nd remission (CR2) rates will be investigated in a randomized
      phase II design. Induction is followed by conventional intensive consolidation. After
      termination of the trial patients may be subjected to an investigational window, before all
      of them receive allo-HSCT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Complete Remission</measure>
    <time_frame>Week 4</time_frame>
    <description>Rate of complete second remission (CR2) quantified by cytology after induction with standard chemotherapy + bortezomib (arm B) compared with standard chemotherapy (arm A).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>Year 3</time_frame>
    <description>Improvement of three years event-free survival (EFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Year 3</time_frame>
    <description>Improvement of three years overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease Reduction (MRD)</measure>
    <time_frame>Week 4</time_frame>
    <description>Improvement of Minimal Residual Disease (MRD) reduction after induction with versus without bortezomib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease Load</measure>
    <time_frame>Week 15</time_frame>
    <description>Improvement of MRD load prior to stem cell transplantation (SCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Residual Disease (MRD)</measure>
    <time_frame>Week 15</time_frame>
    <description>Prognostic relevance of MRD pre stem cell transplantation (SCT). MRD will be quantified before stem cell transplantation with polymerase chain reaction (PCR) and will be related to EFS after SCT. Multicolour flow cytometry will be used in parallel with PCR. Flow cytometry is used instead of PCR if PCR based MRD-quantification cannot be performed, because criteria for a reliable and reproducible sensitive quantification are not fulfilled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Remission/Minimal Residual Disease Rates During Consolidation</measure>
    <time_frame>Week 5, 8, 11, 15</time_frame>
    <description>Improvement of CR2 and/or MRD rates during consolidation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of induction classified with the COMMON TOXICITY CRITERIA (CTC)</measure>
    <time_frame>At induction up to week 5</time_frame>
    <description>Toxicity of induction with versus without bortezomib. Toxicity of the central nervous system and peripheral neuropathy will be classified with the COMMON TOXICITY CRITERIA (CTC).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Minimal Residual Disease in Isolated Extramedullary Relapse</measure>
    <time_frame>Day 0; Week 5, 8, 11, 15</time_frame>
    <description>The rate and extent of sub-microscopic bone marrow (BM) involvement in extramedullary leukemia will be investigated prospectively.</description>
  </other_outcome>
  <other_outcome>
    <measure>Extended Genetic Characterization</measure>
    <time_frame>Day 0</time_frame>
    <description>Extension of genetic characterization and correlation with clinical data</description>
  </other_outcome>
  <other_outcome>
    <measure>In-vitro drug response profile</measure>
    <time_frame>Day 0</time_frame>
    <description>Generation of primografts from patient samples for bio-banking and drug testing by using immunodeficient mice. The outcome measure is the in-vitro drug response profile using the primograft of primary patient sample. The in-vitro drug response profile will be compared to the in-vivo drug response of a patient. In order to get an &quot;in-vitro drug response profile&quot; apoptosis/viability of the primary patient sample or patient-derived xenograft sample is measured using different concentrations of novel drugs normally after 48 hours of treatment. These drugs could be potentially given to a patient, when there will be no response to conventional protocol treatment. Apoptosis/viability is measured by live cell imaging microscopy or/and by flow cytometry. The report will include half maximal inhibitory concentration (IC50), the concentration of a drug which kills half of the cell after a defined time (normally 48h) for a variety of potential drugs.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Acute Lymphoblastic Leukemia (ALL)</condition>
  <arm_group>
    <arm_group_label>Arm HR-A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Induction: Backbone ALL R3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm HR-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Backbone ALL R3 + Bortezomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Patients randomised to the HR-B arm receive induction, consolidation with the modified ALL R3 protocol. In this arm, patients are randomized to receive Bortezomib together with the ALL R3 protocol during induction. Administration of Bortezomib: 1.3 mg/m2 as intravenous bolus or subcutaneously (SC, at the discretion of the treating physician) on days 1 and 4 of weeks 1 and 3.</description>
    <arm_group_label>Arm HR-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Morphologically confirmed diagnosis of 1st relapsed precursor B-cell or T-cell ALL

          -  Children less than 18 years of age at date of inclusion into the study

          -  Meeting HR criteria any BM relapse, early/very early isolated BM relapse, very early
             isolated/combined extramedullary relapse)

          -  Patient enrolled in a participating centre

          -  Written informed consent

          -  Start of treatment falling into the study period

          -  No participation in other clinical trials 30 day prior to study enrolment that
             interfere with this protocol, except trials for primary ALL

        Exclusion Criteria:

          -  Breakpoint cluster region-Abelson (BCR-ABL)/ t(9;22) positive ALL

          -  Pregnancy or positive pregnancy test (urine sample positive for β-humane
             choriongonadotropin (HCG) &gt; 10 U/l)

          -  Sexually active adolescents not willing to use highly effective contraceptive method
             (pearl index &lt;1) until 12 months after end of anti-leukemic therapy

          -  Breast feeding

          -  Relapse post allogeneic stem-cell transplantation

          -  Neuropathy &gt; II°

          -  The whole protocol or essential parts are declined either by patient himself/herself
             or the respective legal guardian

          -  Objection to the study participation by a minor patient, able to object

          -  Any patient being dependent on the investigator

          -  No consent is given for saving and propagation of pseudonymized medical data for study
             reasons

          -  Severe concomitant disease that does not allow treatment according to the protocol at
             the investigator's discretion (e.g. malformation syndromes, cardiac malformations,
             metabolic disorders)

          -  Subjects unwilling or unable to comply with the study procedures

          -  Subjects who are legally detained in an official institute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arend von Stackelberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arend von Stackelberg, MD</last_name>
    <phone>+49(0)30-450666</phone>
    <phone_ext>833</phone_ext>
    <email>arend.stackelberg@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Australian &amp; New Zealand Childhood Hematology &amp; Oncology Group</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Revesz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Anna Kinderkrebsforschung, CCRI</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Mann, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Andishe Atterbashi, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hòpital Universitaire des Enfants Reine Fabiola</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alina Ferster, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Sramkova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital (Rigshospitalet)</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Frandsen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>SF-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Päivi Lähteenmäki, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Rohrlich, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Centre</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronit Elhasid, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prinses Máxima Centrum, Lundlaan</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Hoogerbrugge, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marit Hellebostad, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dpt. SCT and Hematology/Oncology University Wroclaw</name>
      <address>
        <city>Wroclaw</city>
        <zip>50354</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Goczynska, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia de Lisboa</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joaquin Duarte, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Stockholm</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Soderhall, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denise Bonney, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>PD Dr. Arend von Stackelberg</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

